APOGEPHA Arzneimittel GmbH

APOGEPHA is a medium sized, family owned pharmaceutical company with 145 employees and a sales turnover of € 151,1 Million in 2023. We are specialised in urology and markets over 20 prescription and non prescription medicines in different therapeuitc fields, such as prostate cancer, bladder cancer, renal cancer, overactive bladder and urinary incontinence in adults and children and urinary tract infections.
Founded in Dresden in 1882, APOGEPHA stands for more than 140 years of experience and responsibility in pharmacy and medicine. Urological research and product development go back almost as far. Today APOGEPHA is one of the leading German companies in urology.
One important milestone in company’s history was the development of propiverine, a active ingredient in treatment of urinary incontinence. The substance is very succesful in Germany and is marketed internationally under the trademarks Mictonorm Uno® or Detrunorm® in more than 20 countries worldwide, where marketing & sales is carried out by compenent local partners.
We, that is around 145 committed employees, see ourselves not only as a supplier of pharmaceuticals, but as your partner in urology.